廣生堂(300436.SZ):泰甘定丙酚替諾福韋片獲批上市
格隆匯4月23日丨廣生堂(300436.SZ)宣佈,近日,公司收到國家藥監局核准簽發的關於富馬酸丙酚替諾福韋片的《藥品註冊證書》,標誌着泰甘定(公司富馬酸丙酚替諾福韋片商標名)將於2021年7月20日原研專利過期後國內首批上市,實現國產化,為中國乙肝患者提供更多更好的用藥選擇,同時將進一步完善公司的肝病產品管線,打造公司“肝病專家”系列品牌,進一步強化在肝藥領域的市場佔有率和領先地位,為公司提供新的業績增量,以仿哺創,助力公司創新轉型發展。
丙酚替諾福韋用藥劑量更低,且具有更好的骨骼安全性和腎臟安全性,是各國乙肝防治指南一致推薦的一線優先用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.